Physician profile
Stephanie E Guize
NPI 1104933886
$6,438.50
in general payments reported to CMS, 2019-2025
41 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $1,335 · 2023: $1,342 · 2024: $1,839 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,221 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,220.76 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,094.72 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $708.43 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $534.85 | 2021-2025 | |
| Pfizer INC. | $530.17 | 2021-2025 | |
| Astellas Pharma US INC | $483.24 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $402.56 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.19 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals Lp | $252.76 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $217.19 | 2021-2025 | |
| Abbott Laboratories | $201.59 | 2022-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $182.83 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $137.32 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $133.04 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.82 | 2023-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.23 | 2024-2025 | Caplyta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Guize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.